Category:Hematology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 5: Line 5:
== List of Chapters Requiring Content ==
== List of Chapters Requiring Content ==


* Alpha thalassemia
* Microangiopathic hemolytic anemia
* Myelophthisic anemia
* Glucose-6-phosphate dehydrogenase deficiency
* Pupura (LP)
** Papular (SP)
** Infectious (SP)
** Purpura fulminans
* Thrombotic micropangiopathies (LP)
* Hemophilia (LP)
** Hemophilia A
** Hemophilia B
* Neutrophilia (SP)
* Neutropenia (SP)
* Lymphocytosis (SP)
* Monocytosis (SP)
* Eosiniphilia (SP)
* Basophilia (SP)
* Lymphadenopathy (SP)
* Transfusion therapy (SP)
* Transfusion reactions (SP)
* Myeloproliferative neoplasms (LP)




 
<br />
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
! style="background: #4479BA; padding: 5px 5px;" rowspan=1 | {{fontcolor|#FFFFFF|Category}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Category}}
! style="background: #4479BA; padding: 5px 5px;" rowspan=1 | {{fontcolor|#FFFFFF|Chapters that need content}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Chapters that need content}}
! style="background: #4479BA; padding: 5px 5px;" rowspan=1 | {{fontcolor|#FFFFFF|Assignment Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Assignment Status}}
! style="background: #4479BA; padding: 5px 5px;" rowspan=1 | {{fontcolor|#FFFFFF|Scholar's name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Scholar's name}}
! style="background: #4479BA; padding: 5px 5px;" rowspan=1 | {{fontcolor|#FFFFFF|Coach name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Coach name}}
! style="background: #4479BA; padding: 5px 5px;" rowspan=1 | {{fontcolor|#FFFFFF|Completion Status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Completion Status}}
! style="background: #4479BA; padding: 5px 5px;" rowspan=1 | {{fontcolor|#FFFFFF|Review status}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Review status}}
! style="background: #4479BA; padding: 5px 5px;" rowspan=1 | {{fontcolor|#FFFFFF|Reviewer name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" rowspan="21" |Hematology
| rowspan="21" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Hematology
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Alpha thalassemia
* Alpha thalassemia
Line 51: Line 29:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Insert paragraph


* Microangiopathic hemolytic anemia
* Microangiopathic hemolytic anemia
Line 111: Line 86:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* opangiopathies (LP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 120: Line 96:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Hemophilia (LP)(Muhammad)(Abdelrahman)
** Hemophilia A
** Hemophilia B
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 129: Line 108:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Neutrophilia (SP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 138: Line 118:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Neutropenia (SP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 147: Line 128:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Lymphocytosis (SP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 156: Line 138:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Monocytosis (SP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 165: Line 148:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Eosiniphilia (SP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 174: Line 158:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Basophilia (SP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 183: Line 168:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Lymphadenopathy (SP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 192: Line 178:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Transfusion therapy (SP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 201: Line 188:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Transfusion reactions (SP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 210: Line 198:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Myeloproliferative neoplasms (LP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 237: Line 226:
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* opangiopathies (LP)
*  
* Hemophilia (LP)(Muhammad)(Abdelrahman)
** Hemophilia A
** Hemophilia B
* Neutrophilia (SP)
* Neutropenia (SP)
* Lymphocytosis (SP)
* Monocytosis (SP)
* Eosiniphilia (SP)
* Basophilia (SP)
* Lymphadenopathy (SP)
* Transfusion therapy (SP)
* Transfusion reactions (SP)
* Myeloproliferative neoplasms (LP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |

Revision as of 21:54, 19 June 2020


List of Chapters Requiring Content


Category Chapters that need content Assignment Status Scholar's name Coach name Completion Status Review status Reviewer name
Hematology
  • Alpha thalassemia
  • Microangiopathic hemolytic anemia
  • Myelophthisic anemia
  • Glucose-6-phosphate dehydrogenase deficiency
  • Pupura (LP)
    • Papular (SP)
    • Infectious (SP)
    • Purpura fulminans
  • Thrombotic micropangiopathies (LP)
  • opangiopathies (LP)
  • Hemophilia (LP)(Muhammad)(Abdelrahman)
    • Hemophilia A
    • Hemophilia B
  • Neutrophilia (SP)
  • Neutropenia (SP)
  • Lymphocytosis (SP)
  • Monocytosis (SP)
  • Eosiniphilia (SP)
  • Basophilia (SP)
  • Lymphadenopathy (SP)
  • Transfusion therapy (SP)
  • Transfusion reactions (SP)
  • Myeloproliferative neoplasms (LP)


In progress chapters

Completed chapters

Subcategories

This category has the following 6 subcategories, out of 6 total.

B

C

E

H

Pages in category "Hematology"

The following 200 pages are in this category, out of 4,403 total.

(previous page) (next page)

2

5

A

(previous page) (next page)
Retrieved from "https://www.wikidoc.org/index.php?title=Category:Hematology&oldid=1615268"